News Archives - Triferic

Category: News

04 May

Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis

Dialysate FPC iron is a novel option for iron replacement in patients receiving hemodialysis. There are potential advantages compared to IV iron injection. In particular, the quantitative matching of iron losses and replacement are more physiologic with dialysate FPC. The slower delivery rates may help to avoid oxidative stress and other potential safety issues with […]

20 Apr

Triferic Pharmacokinetics Characterized

ORLANDO, Fla.—Triferic (ferric pyrophosphate citrate) administered during hemodialysis (HD) or intravenously rapidly donates iron to transferrin and is cleared quickly from the circulation, according to new findings presented at the National Kidney Foundation’s 2017 Spring Clinical Meetings. The drug, which was approved by the FDA in January 2015 to maintain hemoglobin levels in dialysis patients, […]

09 Mar

How ‘Bundling’ Changed Dialysis Care

Introduction of the federal government’s prospective payment system for dialysis care (“bundling”) in January 1, 2011 has brought about a new frugality and cost-consciousness in the use of medications and other resources in the management of patients with end-stage renal disease (ESRD). Dialysis providers were now being challenged to control costs—especially those associated with medications—while […]

07 Feb

Triferic®—A Unique Iron Replacement that Maintains Hemoglobin

During Kidney Week 2016, Robert L. Chioini, founder, chairman, and chief executive officer of Rockwell Medical presented an overview of Triferic®, the only FDA-approved drug indicated to replace iron at every dialysis treatment and maintain hemoglobin in adult patients with chronic kidney disease (CKD) on a regimen of regular hemodialysis. Triferic (ferric pyrophosphate citrate) was […]